OnKure, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (NCT06239467) | OnKure, Inc. | 2024-02-26 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) (NCT05340621) | OnKure, Inc. | 2022-05-11 |
| A Study of OKI-179 in Patients With Solid Tumors (NCT03931681) | OnKure, Inc. | 2019-05-08 |
Track OnKure, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.